DNAprint Genomics (DNAG)

[ann441j]

And this:

DNAPrint Genomics Appoints Two Scientists to Key Positions
at Computational Biology Division

SARASOTA, FL--May 18, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced the appointment of two experienced scientists to key positions in the Computational Biology Division of DNAPrint Pharmaceuticals, Inc., the Company's wholly owned subsidiary.

Tandy Herren, Ph.D., was named Director of Simulation Technology and Neil Kabrun, Ph.D., Director of Biological Modeling. Dr. Herren will be responsible for applying DNAPrint's proprietary BioFusion(TM) simulation technology, as well as other modeling techniques to support the Company's drug and diagnostics product development programs. Dr. Kabrun is responsible for the acquisition and implementation of a toolbox of techniques and systems that will continue to advance the role of computational methods in improving product development.

Dr. Herren, formerly a scientist at Kenna Technologies, (acquired by DNAPrint Genomics in November 2005) was a co-founder and a co-inventor of the simulation methods currently utilized by DNAPrint Pharmaceuticals. Dr. Kabrun served as an independent consultant before joining DNAPrint Pharmaceuticals.

"DNAPrint Pharmaceuticals has already benefited from the impact of simulation technology in the development stage of the Company's first drug, PT-401, an enhanced form of the blood 'booster drug' erythropoietin," stated Barbara Handelin, Ph.D., DNAPrint General Manager of Computational Biology. "The team of Herren and Kabrun developed a simulation model for PT-401 that provides key insights into PT-401's performance characteristics, including its benefits over conventional forms of erythropoietin. Their work is crucial to our research leading to preclinical studies of PT-401."

"DNAPrint Pharmaceuticals is pleased to have attracted two experienced scientists in this important new field of computational biology," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and head of the DNAPrint Pharmaceuticals subsidiary. "We are committed to the value that computational biology brings to our drug and diagnostic development programs."

Thumbs up!

Ann